Literature DB >> 26688333

Connexins in skeletal muscle development and disease.

Peter A Merrifield1, Dale W Laird2.   

Abstract

Gap junctions consist of clusters of intercellular channels composed of connexins that connect adjacent cells and allow the exchange of small molecules. While the 21 member multi-gene family of connexins are ubiquitously found in humans, only Cx39, Cx40, Cx43 and Cx45 have been documented in developing myoblasts and injured adult skeletal muscle while healthy adult skeletal muscle is devoid of connexins. The use of gap junctional blockers and cultured myoblast cell lines have suggested that these connexins play a critical role in myotube formation and muscle regeneration. More recent genetically-modified mouse models where Cx43 function is greatly compromized or ablated have further supported a role for Cx43 in regulating skeletal muscle development. In the last decade, we have become aware of a cohort of patients that have a development disorder known as oculodentodigital dysplasia (ODDD). These patients harbor either gain or loss of Cx43 function gene mutations that result in many organ anomalies raising questions as to whether they suffer from defects in skeletal muscle formation or regeneration upon injury. Interesting, some ODDD patients report muscle weakness and loss of limb control but it is not clear if this is neurogenic or myogenic in origin. This review will focus on the role connexins play in muscle development and repair and discuss the impact of Cx43 mutants on muscle function. Crown
Copyright © 2015. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Connexin; Gap junctions; Myogenesis; Oculodentodigital dysplasia; Skeletal muscle

Mesh:

Substances:

Year:  2015        PMID: 26688333     DOI: 10.1016/j.semcdb.2015.12.001

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  8 in total

Review 1.  Joint diseases: from connexins to gap junctions.

Authors:  Henry J Donahue; Roy W Qu; Damian C Genetos
Journal:  Nat Rev Rheumatol       Date:  2017-12-19       Impact factor: 20.543

Review 2.  Therapeutic strategies targeting connexins.

Authors:  Dale W Laird; Paul D Lampe
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

3.  Prevention of connexin-43 remodeling protects against Duchenne muscular dystrophy cardiomyopathy.

Authors:  Eric Himelman; Mauricio A Lillo; Julie Nouet; J Patrick Gonzalez; Qingshi Zhao; Lai-Hua Xie; Hong Li; Tong Liu; Xander Ht Wehrens; Paul D Lampe; Glenn I Fishman; Natalia Shirokova; Jorge E Contreras; Diego Fraidenraich
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

4.  Two Different Functions of Connexin43 Confer Two Different Bone Phenotypes in Zebrafish.

Authors:  Akihiro Misu; Hiroaki Yamanaka; Toshihiro Aramaki; Shigeru Kondo; I Martha Skerrett; M Kathryn Iovine; Masakatsu Watanabe
Journal:  J Biol Chem       Date:  2016-04-25       Impact factor: 5.157

Review 5.  Connexins and their channels in inflammation.

Authors:  Joost Willebrords; Sara Crespo Yanguas; Michaël Maes; Elke Decrock; Nan Wang; Luc Leybaert; Brenda R Kwak; Colin R Green; Bruno Cogliati; Mathieu Vinken
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-07-07       Impact factor: 8.250

Review 6.  Inhibitors of connexin and pannexin channels as potential therapeutics.

Authors:  Joost Willebrords; Michaël Maes; Sara Crespo Yanguas; Mathieu Vinken
Journal:  Pharmacol Ther       Date:  2017-07-15       Impact factor: 12.310

7.  Connexin 26 Expression in Mammalian Cardiomyocytes.

Authors:  S Moscato; M Cabiati; F Bianchi; F Vaglini; M A Morales; S Burchielli; L Botta; A R M Sabbatini; A Falleni; S Del Ry; L Mattii
Journal:  Sci Rep       Date:  2018-09-18       Impact factor: 4.379

8.  Connexin-43 reduction prevents muscle defects in a mouse model of manifesting Duchenne muscular dystrophy female carriers.

Authors:  Julie Nouet; Eric Himelman; Kevin C Lahey; Qingshi Zhao; Diego Fraidenraich
Journal:  Sci Rep       Date:  2020-03-30       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.